SEATTLE CHILDREN'S HOSPITAL

An investigational CAR T-cell therapy, bicistronic CD19/CD22, induced complete remission in 99.1% of relapsed or refractory childhood B-ALL patients, with 75.5% EFS and 93.5% OS at 1 year. CRS occurred in all patients, with 45.7% experiencing grade 3/4 events. Consolidative allogeneic stem cell transplant improved EFS but not OS. The therapy aims to address gaps in current treatments, particularly for isolated central nervous system relapses.

The UW Medicine Institute for Translational Immunology has updated its postdoctoral fellowships to better prepare trainees for careers in translational medicine, including non-academic paths. The program includes interdisciplinary training, mentorship, and career-specific education, inspired by COVID-19 research successes. Fellows will also participate in the PROPEL program, mentoring underrepresented college graduates in research.